Abeona Therapeutics Inc. (ABEO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report sent to investors on Monday morning. HC Wainwright currently has a $20.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. Royal Bank Of Canada began coverage on Abeona Therapeutics in a report on Thursday, September 14th. They set an outperform rating and a $23.00 price target on the stock. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the company a buy rating in a report on Tuesday, August 29th. Zacks Investment Research downgraded Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. BidaskClub downgraded Abeona Therapeutics from a buy rating to a hold rating in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald set a $21.00 price target on Abeona Therapeutics and gave the company a buy rating in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company has an average rating of Buy and an average target price of $18.50.

Shares of Abeona Therapeutics (ABEO) opened at 16.50 on Monday. The stock’s 50 day moving average price is $10.74 and its 200 day moving average price is $7.22. The stock’s market capitalization is $664.74 million. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $17.90.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. Analysts expect that Abeona Therapeutics will post ($0.68) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Abeona Therapeutics Inc. (ABEO) Earns Buy Rating from HC Wainwright” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/21/abeona-therapeutics-inc-abeo-earns-buy-rating-from-hc-wainwright.html.

Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Abeona Therapeutics by 869.7% during the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock valued at $580,000 after acquiring an additional 104,038 shares during the last quarter. Family Management Corp purchased a new stake in Abeona Therapeutics during the first quarter valued at $120,000. Private Advisor Group LLC increased its position in Abeona Therapeutics by 50.0% during the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 6,999 shares during the last quarter. Wellington Management Group LLP increased its position in Abeona Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after acquiring an additional 30,300 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at $594,000. Institutional investors own 38.24% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply